The association between ACE inhibitors and psoriasis based on the drug-targeted Mendelian randomization and real-world pharmacovigilance analyses

References

• Chang HW, Yan D, Singh R, et al. Multiomic analysis of the gut microbiome in psoriasis reveals distinct host‒microbe associations. JID Innov. 2022 May;2(3):100115. doi: 10.1016/j.xjidi.2022.100115
   PubMedGoogle Scholar
• Murdaca G, Tonacci A, Negrini S, et al. Emerging role of vitamin D in autoimmune diseases: an update on evidence and therapeutic implications. Autoimmun Rev. 2019 Sep;18(9):102350. doi: 10.1016/j.autrev.2019.102350
   PubMed Web of Science ®Google Scholar
• Murdaca G, Gerosa A, Paladin F, et al. Vitamin D and microbiota: is there a link with allergies? Int J Mol Sci. 2021 Apr 20;22(8):4288. doi: 10.3390/ijms22084288
   PubMed Web of Science ®Google Scholar
• Murdaca G, Greco M, Borro M, et al. Hygiene hypothesis and autoimmune diseases: a narrative review of clinical evidences and mechanisms. Autoimmun Rev. 2021 Jul;20(7):102845. doi: 10.1016/j.autrev.2021.102845
   PubMed Web of Science ®Google Scholar
• Brożyna AA, Slominski RM, Nedoszytko B, et al. Vitamin D Signaling in Psoriasis: Pathogenesis and Therapy. Int J Mol Sci. 2022 Aug 2;23(15):8575. doi: 10.3390/ijms23158575
   PubMed Web of Science ®Google Scholar
• Campione E, Cosio T, Di Prete M, et al. Experimental Pharmacological Management of Psoriasis. J Exp Pharmacol. 2021;13:725–37. doi: 10.2147/JEP.S265632
   PubMedGoogle Scholar
• Campione E, Mazzilli S, Di Prete M, et al. The role of Glutathione-S Transferase in psoriasis and associated comorbidities and the effect of dimethyl fumarate in this pathway. Front Med. 2022;9(760852): doi: 10.3389/fmed.2022.760852
   Google Scholar
• Kulig P, S Musiol S, Freiberger N, et al. IL-12 protects from psoriasiform skin inflammation. Nat Commun. 2016 Nov 28;7(13466). doi: 10.1038/ncomms13466
   PubMedGoogle Scholar
• Takeshita J, S Grewal S, Langan M, et al. Psoriasis and comorbid diseases: Epidemiology. J Am Acad Dermatol. 2017 Mar;76(3):377–90. doi: 10.1016/j.jaad.2016.07.064
   PubMed Web of Science ®Google Scholar
• Gallo G, Volpe M, Rubattu S. Angiotensin receptor blockers in the management of Hypertension: a real-world perspective and Current recommendations. Vasc Health Risk Manag. 2022;18:507–15. doi: 10.2147/VHRM.S337640
   PubMed Web of Science ®Google Scholar
• Cohen AD, Bonneh DY, Reuveni H, et al. Drug exposure and psoriasis vulgaris: case-control and case-crossover studies. Acta Derm Venereol. 2005;85(4):299–303. doi: 10.1080/00015550510032823
   PubMed Web of Science ®Google Scholar
• Brauchli YB, Jick SS, Curtin F, et al. Association between beta-blockers, other antihypertensive drugs and psoriasis: population-based case-control study. Br J Dermatol. 2008 Jun;158(6):1299–307. doi: 10.1111/j.1365-2133.2008.08563.x
   PubMed Web of Science ®Google Scholar
• Gerdes S, Zahl VA, Knopf H, et al. Comedication related to comorbidities: a study in 1203 hospitalized patients with severe psoriasis. Br J Dermatol. 2008 Nov;159(5):1116–1123. doi: 10.1111/j.1365-2133.2008.08786.x
   PubMed Web of Science ®Google Scholar
• Al-Mutairi N, Al-Farag S, Al-Mutairi A, et al. Comorbidities associated with psoriasis: an experience from the middle east. J Dermatol. 2010 Feb;37(2):146–155. doi: 10.1111/j.1346-8138.2009.00777.x
   PubMed Web of Science ®Google Scholar
• Thakor P, Padmanabhan M, Johnson A, et al. Ramipril-induced generalized pustular psoriasis: case report and literature review. Am J Ther. 2010 Jan;17(1):92–95. doi: 10.1097/MJT.0b013e31818f9e99
   PubMed Web of Science ®Google Scholar
• Wu S, Han J, Li WQ, et al. Hypertension, antihypertensive medication use, and risk of psoriasis. JAMA Dermatol. 2014 Sep;150(9):957–963. doi: 10.1001/jamadermatol.2013.9957
   PubMed Web of Science ®Google Scholar
• Kim HN, Han K, Song SW, et al. Hypertension and risk of psoriasis incidence: an 11-year nationwide population-based cohort study. PLoS One. 2018;13(8):e0202854. doi: 10.1371/journal.pone.0202854
   PubMed Web of Science ®Google Scholar
• Ohyama K, Arai H, Sugiura M, et al. Psoriasis associated with ACE inhibitors: an analysis of the FAERS database. Pharmazie. 2020 Oct 1;75(10):524–526. doi: 10.1691/ph.2020.0606
   PubMed Web of Science ®Google Scholar
• Song G, Kim JY, Yoon HY, et al. A systematic review and meta-analysis of angiotensin-converting enzyme inhibitor use and psoriasis incidence. Sci Rep. 2021 May 11;11(1):10037. doi: 10.1038/s41598-021-89490-z
   PubMed Web of Science ®Google Scholar
• Song G, Yoon HY, Yee J, et al. Antihypertensive drug use and psoriasis: a systematic review, meta- and network meta-analysis. Br J Clin Pharmacol. 2022 Mar;88(3):933–941. doi: 10.1111/bcp.15060
   PubMed Web of Science ®Google Scholar
• Smith GD, Ebrahim S. ‘Mendelian randomization’: can genetic epidemiology contribute to understanding environmental determinants of disease? Int J Epidemiol. 2003 Feb;32(1):1–22. doi: 10.1093/ije/dyg070
   PubMed Web of Science ®Google Scholar
• Emdin CA, Khera AV, Kathiresan S. Mendelian Randomization. JAMA. 2017 Nov 21;318(19):1925–1926. doi: 10.1001/jama.2017.17219
   PubMed Web of Science ®Google Scholar
• Li Y, Li Q, Cao Z, et al. The causal association of polyunsaturated fatty acids with allergic disease: a two-sample Mendelian randomization study. Front Nutr. 2022;9(962787): doi: 10.3389/fnut.2022.962787
   Google Scholar
• Zheng J, Haberland V, Baird D, et al. Phenome-wide Mendelian randomization mapping the influence of the plasma proteome on complex diseases. Nat Genet. 2020 Oct;52(10):1122–1131. doi: 10.1038/s41588-020-0682-6
   PubMed Web of Science ®Google Scholar
• Yarmolinsky J, Díez-Obrero V, Richardson TG, et al. Genetically proxied therapeutic inhibition of antihypertensive drug targets and risk of common cancers: a mendelian randomization analysis. PLOS Med. 2022 Feb;19(2):e1003897. doi: 10.1371/journal.pmed.1003897
   PubMed Web of Science ®Google Scholar
• Lin J, Zhou J, Xu Y. Potential drug targets for multiple sclerosis identified through Mendelian randomization analysis. Brain. 2023 Aug 1;146(8):3364–72. doi: 10.1093/brain/awad070
   PubMed Web of Science ®Google Scholar
• Hemani G, Zheng J, Elsworth B, et al. The MR-Base platform supports systematic causal inference across the human phenome. eLife. 2018 May 30;7:e34408. doi: 10.7554/eLife.34408
   PubMed Web of Science ®Google Scholar
• Loh PR, Kichaev G, Gazal S, et al. Mixed-model association for biobank-scale datasets. Nat Genet. 2018 Jul;50(7):906–908. doi: 10.1038/s41588-018-0144-6
   PubMed Web of Science ®Google Scholar
• Mbatchou J, Barnard L, Backman J, et al. Computationally efficient whole-genome regression for quantitative and binary traits. Nat Genet. 2021 Jul;53(7):1097–1103. doi: 10.1038/s41588-021-00870-7
   PubMed Web of Science ®Google Scholar
• Huang W, Xiao J, Ji J, et al. Association of lipid-lowering drugs with COVID-19 outcomes from a Mendelian randomization study. Elife. 2021 Dec 6;10. doi: 10.7554/eLife.73873
   Web of Science ®Google Scholar
• Xie W, Li J, Du H, et al. Causal relationship between PCSK9 inhibitor and autoimmune diseases: a drug target Mendelian randomization study. Arthritis Res Ther. 2023 Aug 14;25(1):148. doi: 10.1186/s13075-023-03122-7
   PubMed Web of Science ®Google Scholar
• Kurki MI, Karjalainen J, Palta P, et al. FinnGen provides genetic insights from a well-phenotyped isolated population. Nature. 2023 Jan;613(7944):508–518. doi: 10.1038/s41586-022-05473-8
   PubMed Web of Science ®Google Scholar
• Sakaue S, Kanai M, Tanigawa Y, et al. A cross-population atlas of genetic associations for 220 human phenotypes. Nat Genet. 2021 Oct;53(10):1415–1424. doi: 10.1038/s41588-021-00931-x
   PubMed Web of Science ®Google Scholar
• Burgess S, Butterworth A, Thompson SG. Mendelian randomization analysis with multiple genetic variants using summarized data. Genet Epidemiol. 2013 Nov;37(7):658–665. doi: 10.1002/gepi.21758
   PubMed Web of Science ®Google Scholar
• Greco MF, Minelli C, Sheehan NA, et al. Detecting pleiotropy in Mendelian randomisation studies with summary data and a continuous outcome. Stat Med. 2015 Sep 20;34(21):2926–40. doi: 10.1002/sim.6522
   PubMed Web of Science ®Google Scholar
• Burgess S, Thompson G. Interpreting findings from Mendelian randomization using the MR-Egger method. Eur J Epidemiol. 2017 May;32(5):377–89. doi: 10.1007/s10654-017-0255-x
   PubMed Web of Science ®Google Scholar
• Sakaeda T, Tamon A, Kadoyama K, et al. Data mining of the public version of the FDA adverse event reporting system. Int J Med Sci. 2013;10(7):796–803. doi: 10.7150/ijms.6048
   PubMed Web of Science ®Google Scholar
• Bai Y, Wu B, Gou L, et al. Cardiovascular safety evaluation of Febuxostat and allopurinol: findings from the FDA adverse event reporting system. J Clin Med. 2023 Sep 20;12(18):6089. doi: 10.3390/jcm12186089
   PubMed Web of Science ®Google Scholar
• Zhou C, Peng S, Lin A, et al. Psychiatric disorders associated with immune checkpoint inhibitors: a pharmacovigilance analysis of the FDA adverse event reporting system (FAERS) database. EClinicalMedicine. 2023 May;59(101967):101967. doi: 10.1016/j.eclinm.2023.101967
   PubMedGoogle Scholar
• Ramezani M, Zavattaro E, Sadeghi M. Angiotensin-converting enzyme gene insertion/deletion polymorphism and susceptibility to psoriasis: a systematic review and meta-analysis. BMC Med Genet. 2020 Jan 8;21(1):8. doi: 10.1186/s12881-019-0943-3
   PubMed Web of Science ®Google Scholar
• Chang YC, Wu WM, Chen CH, et al. Association between the insertion/deletion polymorphism of the angiotensin I-converting enzyme gene and risk for psoriasis in a Chinese population in Taiwan. Br J Dermatol. 2007 Apr;156(4):642–645. doi: 10.1111/j.1365-2133.2006.07716.x
   PubMed Web of Science ®Google Scholar
• Weger W, Hofer A, Wolf P, et al. The angiotensin-converting enzyme insertion/deletion and the endothelin -134 3A/4A gene polymorphisms in patients with chronic plaque psoriasis. Exp Dermatol. 2007 Dec;16(12):993–998. doi: 10.1111/j.1600-0625.2007.00620.x
   PubMed Web of Science ®Google Scholar
• Yang K, Zhang F, Li F, et al. Angiotensin-converting enzyme insertion/deletion polymorphism and susceptibility to psoriasis in a Chinese population. J Renin Angiotensin Aldosterone Syst. 2014 Mar;15(1):39–43. doi: 10.1177/1470320313494433
   PubMed Web of Science ®Google Scholar
• Costerousse O, Allegrini J, Lopez M, et al. Angiotensin I-converting enzyme in human circulating mononuclear cells: genetic polymorphism of expression in T-lymphocytes. Biochem J. 1993 Feb 15;290(Pt 1):33–40. doi: 10.1042/bj2900033
   PubMedGoogle Scholar
• Munir S, Rahman B, Rehman S, et al. The angiotensin-converting enzyme gene insertion polymorphism: a higher risk for psoriasis in male patients. Br J Dermatol. 2016 Oct;175(4):824–6. doi: 10.1111/bjd.14653
   PubMed Web of Science ®Google Scholar
• Taddei S, Bortolotto L. Unraveling the pivotal role of bradykinin in ACE inhibitor activity. Am J Cardiovasc Drugs. 2016 Oct;16(5):309–321. doi: 10.1007/s40256-016-0173-4
   PubMed Web of Science ®Google Scholar
• Rex DAB, Vaid N, Deepak K, et al. A comprehensive review on current understanding of bradykinin in COVID-19 and inflammatory diseases. Mol Biol Rep. 2022 Oct;49(10):9915–27. doi: 10.1007/s11033-022-07539-2
   PubMed Web of Science ®Google Scholar
• Kutwin M, Woźniacka A. Interleukins 20 and 8 - less widely known cytokines in psoriasis. Postepy Dermatol Alergol. 2023 Apr;40(2):194–203. doi: 10.5114/ada.2022.119077
   PubMed Web of Science ®Google Scholar
• Komatsu N, Saijoh K, Kuk C, et al. Aberrant human tissue kallikrein levels in the stratum corneum and serum of patients with psoriasis: dependence on phenotype, severity and therapy. Br J Dermatol. 2007 May;156(5):875–883. doi: 10.1111/j.1365-2133.2006.07743.x
   PubMed Web of Science ®Google Scholar
• Scholzen T, Armstrong CA, Bunnett NW, et al. Neuropeptides in the skin: interactions between the neuroendocrine and the skin immune systems. Exp Dermatol. 1998 Apr;7(2–3):81–96. doi: 10.1111/j.1600-0625.1998.tb00307.x
   PubMed Web of Science ®Google Scholar
• Yu XJ, Ren XH, Xu YH, et al. Vasoactive intestinal peptide induces vascular endothelial growth factor production in human HaCaT keratinocytes via MAPK pathway. Neuropeptides. 2010 Oct;44(5):407–411. doi: 10.1016/j.npep.2010.05.002
   PubMed Web of Science ®Google Scholar
• Mashaghi A, Marmalidou A, Tehrani M, et al. Neuropeptide substance P and the immune response. Cell Mol Life Sci. 2016 Nov;73(22):4249–64. doi: 10.1007/s00018-016-2293-z
   PubMed Web of Science ®Google Scholar
• Naukkarinen A, Nickoloff BJ, Farber EM. Quantification of cutaneous sensory nerves and their substance P content in psoriasis. J Invest Dermatol. 1989 Jan;92(1):126–129. doi: 10.1111/1523-1747.ep13071340
   PubMed Web of Science ®Google Scholar
• Reich A, Orda A, Wiśnicka B, et al. Plasma concentration of selected neuropeptides in patients suffering from psoriasis. Exp Dermatol. 2007 May;16(5):421–8. doi: 10.1111/j.1600-0625.2007.00544.x
   PubMed Web of Science ®Google Scholar
• Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: a review. JAMA. 2020 May 19;323(19):1945–1960. doi: 10.1001/jama.2020.4006
   PubMed Web of Science ®Google Scholar
• Lou F, Sun Y, Xu Z, et al. Excessive polyamine generation in keratinocytes promotes self-RNA sensing by dendritic cells in psoriasis. Immunity. 2020 Jul 14;53(1):204–16.e10. doi: 10.1016/j.immuni.2020.06.004
   PubMed Web of Science ®Google Scholar
• Mishra A, Lal G. Neurokinin receptors and their implications in various autoimmune diseases. Curr Res Immunol. 2021;2:66–78. doi: 10.1016/j.crimmu.2021.06.001
   PubMedGoogle Scholar
• Zhang J, Zhao S, Xing X, et al. Effects of neuropeptides on Dendritic cells in the pathogenesis of psoriasis. J Inflamm Res. 2023;Volume 16:16(35–43. doi: 10.2147/JIR.S397079
   Web of Science ®Google Scholar
• Sangole NV, Dadkar VN. Adverse drug reaction monitoring with angiotensin converting enzyme inhibitors: a prospective, randomized, open-label, comparative study. Indian J Pharmacol. 2010 Feb;42(1):27–31. doi: 10.4103/0253-7613.62408
   PubMed Web of Science ®Google Scholar